BRAF and metastatic malignant neoplasm in the lymph nodes: The quantitative analysis of BRAF mutant alleles showed a significant difference between PTCs presenting with lymph node metastases as compared to PTCs without metastases (27.6% vs. 18.4% respectively; p = 0.03).